-- Israeli Stocks: Teva, Partner, Cellcom Israel, Satcom, BioLineRx
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-01-29T15:21:37Z
-- http://www.bloomberg.com/news/2012-01-29/israeli-stocks-teva-partner-cellcom-israel-satcom-biolinerx.html
Israel’s  TA-25 Index (TA-25)  declined 0.8
percent, the most since Jan. 24, to 1,120.80 at the 4:30 p.m.
close in  Tel Aviv . Investors traded about 519 million shekels
($139 million) of shares and convertible securities, according
to bourse data.  The following stocks rose or fell today. Symbols are in
parentheses.  BioLineRx Ltd. (BLRX)   tumbled 7.4 percent to 1.506
shekels, or the equivalent of 40 cents, the lowest level Jan.
23. The biopharmaceutical company’s American depositary
receipts, each representing 10 shares, declined 1 percent to
$3.96 in New York on Jan. 27.  Cellcom Israel Ltd. (CEL)   retreated to the lowest on
record, sliding 4.6 percent to 53.90 shekels, or the equivalent
of $14.39. The New York-traded shares of  Israel ’s largest
mobile-phone company closed at $14.62 on Jan. 27. Concern that
competition will increase pushed the shares lower, said Sabina
Podval, an analyst at Leader & Co. Investment House Ltd.  Partner
Communications Co. (PTNR)  , the second-biggest mobile
provider, dropped 4 percent to 29.38 shekels, or the equivalent
of $7.84, the lowest since October 2004. The U.S.-traded shares
fell 1.9 percent to $7.61.  Delek Real Estate Ltd. (DLKR)   dropped 3.7 percent, the
most since Jan. 24, to 0.264 shekel. The holders of the property
company’s Series 25 notes said a meeting on Jan. 26 was
inconclusive.  Satcom Systems Ltd. (STCM)   soared the most on record,
advancing 61 percent to 2.899 shekels. Eurocom Communications
Ltd. increased its offer to purchase the remaining shares of the
communications services provider to 3 shekels a share from 1.8
shekels.  Teva Pharmaceutical Industries Ltd. (TEVA)   declined the
most in a month, retreating 2.7 percent to 168 shekels, or the
equivalent of $44.84. The U.S.-traded shares of the world’s
largest maker of generic pharmaceuticals closed at $44.91 on
Jan. 27. A competitor received clearance to sell a generic
version of Lovenox and a unit recalled a drug.  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  